How does screening for Type 1 help? Doesn't it risk causing fear when none is needed? If done at 3 years old how will it detect type 1 diabetes in someone a few months to a few years later? If it can find out a young child is at risk can anything be done to prevent the Type 1 diabetes from developing or will just cause worry when nothing can be done until it has actually developed?
Appreciate is can be fear inducing, especially if the result is positive, however, there are several benefits to being screened for type 1 diabetes:
- Helps the researchers find children at risk of the condition – the sooner they screen, the sooner they can intervene.
- Allows them to follow-up children at risk so that they can start treatment sooner, before the child becomes too unwell.
- Prevents admission to hospital with diabetic ketoacidosis
- Enables high risk children to enter research trials testing new treatments to delay the start of type 1
The screening is particularly looking at the number of different types of autoantibodies present in the blood which indicates risk of developing type 1 diabetes. If a child (who is 3 for example) is screened and found to have one autoantibody, they have a higher risk of developing type 1 in the future than someone who has no autoantibodies. Autoantibodies can increase, stay the same or decrease over time. Therefore, it might be helpful to have the child re-tested later on to keep an eye on this. If a child has two or more autoantibodies, type 1 diabetes has started to develop. The likelihood of being diagnosed with the condition within the next 15 years is around 85% - so this gives some kind of time-frame, but also there's almost a 100% chance of a diagnosis in their lifetime.
As part of the ELSA Study, if children in the study test positive for type 1 autoantibodies, they will be invited to take part in an education session to help prepare them (and parents) for a diagnosis of type 1 diabetes. Those at risk can also be invited onto immunotherapy trials designed to slow down or stop the immune system attack. One clinical trial has found an immunotherapy drug, called teplizumab (although MHRA is still reviewing this for approval and even then needs to be made available on the NHS if this was to be rolled out UK-wide), delays a diagnosis of type 1 by three years on average when given to people at high risk of developing the condition. The children in the ELSA Study will be invited to take part in this kind of trial, as well as, other immunotherapy clinical trials.
Part of this particular section on the forum is to offer a place, to those parents whose children test positive, support and further practical guidance from parents here in our community who can share their lived experiences on having a child with type 1 diabetes, how they managed diagnoses and more related experiences.